lead us to conclude that adiponectin could be accountable for degradation of the cartilage. Rather, increased levels of adiponectin may be a secondary phenomenon to the late stage of OA, which could be deemed an indication of severity. Another explanation could be that increased levels of adiponectin may serve as a protective response to the catabolic process in OA. Th e current under standing of cytokines and growth factors has been shown incapable of determining a single factor that could be responsible for all chondrocyte responses [3] .
Another point to be raised in this study would be the eff ect of adiponectin on OA cartilage and primary chondrocytes in vitro. Koskinen and colleagues reported that adiponectin enhanced nitric oxide, IL-6, matrix metalloproteinase-1 and matrix metalloproteinase-3 produc tion in primary OA chondrocytes in a dose-dependent manner [1] . However, the authors only investigated factors involved in the degradation of cartilage. Adiponectin may have a dual eff ect on cartilage homeostasis, because it may also stimulate anabolic mediators such as tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metallo proteinase-2 in addition to catabolic mediators [4] . Adiponectin may be involved in the joint metabolism by changing the balance of matrix metalloproteinases and tissue inhibitors of metalloproteinases [4] .
In a cross-sectional study, as a result, studying a single molecule does not solve the mystery of cartilage destruction. A more versatile approach is required to determine the mechanism of cartilage destruction in OA.
